Center for HIV/AIDS Vaccine Immunology (CHAVI) Addendum to RFA-AI-04-051

Notice Number: NOT-AI-05-024

Key Dates
Release Date: February 10, 2005
Letter of Intent:  January 21, 2005
Application Receipt Date:  February 23, 2005
Expiration Date:  February 24, 2005

Issued by
National Institute of Allergy and Infectious Diseases (NIAID), (

The National Institute of Allergy and Infectious Diseases is amending RFA-AI-04-051 [Release Date: September 30, 2004] (, entitled “Centers for HIV/AIDS Vaccine Immunology (CHAVI) ” as follows:

Under Section V. Application Review Information, 3.A. Additional Review Criteria.

Replace the section titled “Overall Evaluation and Scoring” with the text below. NOTE: Reviewers will now be asked to assign specific weights to components of the application.

Additional Review Criteria

In addition to the above criteria, the following items will be considered in the determination of scientific merit and the priority score:

Overall Evaluation and Scoring

The overall application score will be based on review and merit of the individual components as well as the merit of the application taken as a whole. A single numerical priority score will be assigned to the whole application after consideration of all of the elements listed below. PLEASE NOTE THAT THE MOST CRUCIAL FACTORS IN EVALUATION OF THE APPLICATION ARE THE SCIENTIFIC AGENDA AND STRATEGIC PLAN, THE RESEARCH PROGRAM, AND THE DEMONSTRATED CAPACITY TO IMPLEMENT AND MANAGE THE SCIENTIFIC AGENDA, STRATEGIC PLAN AND RESEARCH PROGRAM. Reviewers will be asked to weight the components of the application as follows:

1) The Scientific Agenda/Strategic Plan 30% ; (2) the Management and Operations Group 30% ; (3) the research and development plans of the CHAVI Director and the CHAVI SLG, and the CHAVI Director's documented experience in directing large, complex, integrated and multifaceted research activities 30% ; and (4) shared scientific resources/facilities 10% .

2) The overall score for the application will be based on the scientific merit and weight of the individual components as well as the overall synergy and integration of the components, the effectiveness and adequacy of plans for developing and managing CHAVI, the overall program organization and capability of the associated personnel, the plans for expansion through addition of new research activities and PIs after year one, and the extent to which the proposed Center will contribute to the AIDS vaccine research, development and evaluation effort.


Applicants are encouraged to contact NIH NIAID staff to discuss the proposed amendment.

For questions or further information, contact:

Dr. Stuart Z. Shapiro.
Division of AIDS
National Institute of Allergy and Infectious Diseases
6700-B Rockledge Drive
Room 5146, MSC-7628
Bethesda, MD 20892
Phone: (301) 402-0122
Fax: (301) 402-3684

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.